Pathalys Pharma

Pathalys Pharma is a late-stage clinical biopharmaceutical company focused on developing treatments for end-stage kidney disease (ESKD). Their lead asset is upacicalcet, a novel calcimimetic, and they are actively pursuing other solutions for ESKD patients. The company was co-founded by Catalys Pacific and DaVita Venture Group.

Funding Round: Series B

Funding Amount: $105M

Date: 20-Aug-2024

Investors: TCGX, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, Catalys Pacific, DaVita Venture Group

Markets: Biopharmaceutical, Healthtech, Biotechnology, Pharmaceuticals, Drug Discovery

HQ: Raleigh, North Carolina, United States

Founded: 2021

Website: https://www.pathalys.com/

LinkedIn: https://www.linkedin.com/company/pathalys

Twitter: https://twitter.com/PathalysPharma

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/pathalys?utm_source=linkedin&utm_medium=referral&utm_campaign=linkedin_companies&utm_content=profile_cta_anon&trk=funding_crunchbase

Pitchbook: https://pitchbook.com/profiles/company/469565-11